Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multicenter, Parallel-group Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

NCT05664061 is registered in ClinicalTrials.gov with Respirent Pharmaceuticals Co Ltd. as lead sponsor.

NCT NCT05664061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05664061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multicenter, Parallel-group Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Lead sponsor
Respirent Pharmaceuticals Co Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
January 30, 2023
Completion date
December 31, 2023
Enrollment
451 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma